MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 67-78

  Christensen, Lise Lotte ^a   Tobiasen, Heidi ^a   Holm, Anja ^a   Schepeler, Troels ^a   Ostenfeld, Marie S ^a   Thorsen, Kasper ^a   Rasmussen, Mads H ^a   Birkenkamp Demtroeder, Karin ^a   Sieber, Oliver M ^b,c   Gibbs, Peter ^b,c,d   Lubinski, Jan ^e   Lamy, Philippe ^a   Laurberg, Søren ^a   Øster, Bodil ^a   Hansen, Kristian Q ^a   Hagemann Madsen, Rikke ^a   Byskov, Kristina ^f   Ørntoft, Torben F ^a   Andersen, Claus L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d Royal Melbourne and Western Hospital ^*  (Australia)

^e POMERANIAN MEDICAL UNIVERSITY   (Poland)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

colorectal cancer; miR 362 3p; miRNA expression profiling; recurrence; target identification

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 148A; MICRORNA 362 3P; MICRORNA 570; MICRORNA 944; PROTEIN TYROSINE PHOSPHATASE 1B; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; UPSTREAM STIMULATORY FACTOR 2;

ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; E2F1 GENE; FEMALE; GENE; GENE DOSAGE; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MICROSATELLITE MARKER; PRIORITY JOURNAL; PTPN1 GENE; USF2 GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; COLON; COLORECTAL NEOPLASMS; E2F1 TRANSCRIPTION FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTESTINAL MUCOSA; MALE; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UPSTREAM STIMULATORY FACTORS;

EID: 84876673829     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28010     Document Type: Article

References (48)

1. Boyle P, Langman JS,. ABC of colorectal cancer: epidemiology. BMJ 2000; 321: 805-8.
2. Baddi L, Benson A, III,. Adjuvant therapy in stage II colon cancer: current approaches. Oncologist 2005; 10: 325-31.
3. Rousseau B, Chibaudel B, Bachet JB, et al. Stage II and stage III colon cancer: treatment advances and future directions. Cancer J 2010; 16: 202-9.
4. Zlobec I, Lugli A,. Prognostic and predictive factors in colorectal cancer. Postgrad Med J 2008; 84: 403-11.
5. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
6. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
7. Benes V, Castoldi M,. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 2010; 50: 244-9.
8. Li W, Ruan K,. MicroRNA detection by microarray. Anal Bioanal Chem 2009; 394: 1117-24.
9. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007; 7: 36.
10. Garzon R, Calin GA, Croce CM,. MicroRNAs in Cancer. Annu Rev Med 2009; 60: 167-79.
11. Schepeler T, Reinert JT, Ostenfeld MS, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-24.
12. Arndt GM, Dossey L, Cullen LM, et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009; 9: 374.
13. Schetter AJ, Nguyen GH, Bowman ED, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 2009; 15: 5878-87.
14. Motoyama K, Inoue H, Takatsuno Y, et al. Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 2009; 34: 1069-75.
15. Schetter AJ, Leung SY, Sohn JJ, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-36.
16. Balaguer F, Link A, Lozano JJ, et al. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res 2010; 70: 6609-18.
17. Diosdado B, van de Wiel MA, Terhaar Sive Droste JS, et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. Br J Cancer 2009; 101: 707-14.
18. Sarver AL, French AJ, Borralho PM, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 2009; 9: 401.
19. Lanza G, Ferracin M, Gafa R, et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer 2007; 6: 54.
20. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385-92.
21. Nagel R, le SC, Diosdado B, et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. Cancer Res 2008; 68: 5795-802.
22. Ng EK, Tsang WP, Ng SS, et al. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer 2009; 101: 699-706.
23. Tsang WP, Ng EK, Ng SS, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 2010; 31: 350-8.
24. Diaz R, Silva J, Garcia JM, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008; 47: 794-802.
25. Akcakaya P, Ekelund S, Kolosenko I, et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int J Oncol 2011; 39: 311-8.
26. Nielsen BS, Jorgensen S, Fog JU, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis 2011; 28: 27-38.
27. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
28. Andersen CL, Jensen JL, Orntoft TF,. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64: 5245-50.
29. TargetScan. Available at: http://www.targetscan.org/. February 2012.
30. Ensembl. Available at: http://www.ensembl.org/. February 2012.
31. Saeed AI, Bhagabati NK, Braisted JC, et al. TM4 microarray software suite. Methods Enzymol 2006; 411: 134-93.
32. Wang S, Wang L, Zhu T, et al. Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics 2010; 11: 163.
33. Chi SW, Zang JB, Mele A, et al. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009; 460: 479-86.
34. Van dA, I, Limame R, van DP, et al. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer 2010; 103: 532-41.
35. Yu Z, Baserga R, Chen L, et al. microRNA, cell cycle, and human breast cancer. Am J Pathol 2010; 176: 1058-64.
36. Huang S, He X,. The role of microRNAs in liver cancer progression. Br J Cancer 2011; 104: 235-40.
37. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-73.
38. Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010; 466: 835-40.
39. Wu L, Timmers C, Maiti B, et al. The E2F1-3 transcription factors are essential for cellular proliferation. Nature 2001; 414: 457-62.
40. Chen HZ, Tsai SY, Leone G,. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-97.
41. Iwamoto M, Banerjee D, Menon LG, et al. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther 2004; 3: 395-9.
42. Bramis J, Zacharatos P, Papaconstantinou I, et al. E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas. Anticancer Res 2004; 24: 3041-7.
43. Sirito M, Walker S, Lin Q, et al. Members of the USF family of helix-loop-helix proteins bind DNA as homo- as well as heterodimers. Gene Expr 1992; 2: 231-40.
44. Finotti A, Treves S, Zorzato F, et al. Upstream stimulatory factors are involved in the P1 promoter directed transcription of the A beta H-J-J locus. BMC Mol Biol 2008; 9: 110.
45. Wang J, de la Monte SM, Sabo E, et al. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol 2007; 38: 17-25.
46. Lessard L, Stuible M, Tremblay ML,. The two faces of PTP1B in cancer. Biochim Biophys Acta 2010; 1804: 613-9.
47. Zhu S, Bjorge JD, Fujita DJ,. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 2007; 67: 10129-37.
48. Cortesio CL, Chan KT, Perrin BJ, et al. Calpain 2 and PTP1B function in a novel pathway with Src to regulate invadopodia dynamics and breast cancer cell invasion. J Cell Biol 2008; 180: 957-71.